A Study Using Radiation Therapy and Temozolomide to Treat Glioblastoma in Patients Over 70
A Phase I/ II Study of Hypofractionated Radiotherapy With Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients Over 70 Years Old With Newly Diagnosed Glioblastoma
Sponsor: James Graham Brown Cancer Center
Listed as NCT01985087, this PHASE1/PHASE2 trial focuses on Glioblastoma and remains ongoing. Sponsored by James Graham Brown Cancer Center, it has been updated 11 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Nov 2024 — Present [monthly]
Active Not Recruiting PHASE1/PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Nov 2021 — Jul 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2021 — Nov 2021 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 6 earlier versions
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2019 — Oct 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Jan 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- James Graham Brown Cancer Center
- University of Louisville
For direct contact, visit the study record on ClinicalTrials.gov .